Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Chief Commercial Officer | March 19, 2018 | March 21, 2018 |
| BioStem Technologies, Inc.BSEM · Entity 7054 | Director | August 27, 2026 | August 28, 2026 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Chief Commercial Officer | January 02, 2020 | January 03, 2020 |
| MetaVia Inc.MTVA · Entity 7947 | Director | June 08, 2026 | June 08, 2026 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Co-Chief Executive Officer | December 06, 2022 | December 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aralez Pharmaceuticals Inc.
Report date March 19, 2018 · Filed March 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 250,188 |
Reported balance
After 2018-03-19 transaction · row 1
1 source rowRow 1 · 2018-03-19 · Sale · Disposed 5,725 · Balance 250,188 F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 15,184 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 15,184 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018.
BioStem Technologies, Inc.
Report date August 27, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,671 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Exercise / conversion · Acquired 7,671 · Balance 7,671 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-27 · Exercise / conversion · Disposed 7,671 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: These restricted stock units vested on August 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: These restricted stock units vested on August 27, 2026.
Esperion Therapeutics, Inc.
Report date January 02, 2020 · Filed January 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,925 |
Reported balance
After 2020-01-02 transaction · row 1
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 5,925 · Balance 25,925 F1: The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020. |
| Stock Option (right to buySEC Table II · derivative / convertible security · Conversion / exercise price $61.34 · Expires 2030-01-02 | Direct | 26,625 |
Reported balance
After 2020-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-02 · Grant · Acquired 26,625 · Balance 26,625 F1: The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020.
MetaVia Inc.
Report date June 08, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,629 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 17,186 · Balance 20,629 F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date.
F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025.
TherapeuticsMD, Inc.
Report date December 06, 2022 · Filed December 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,294 |
Ending reported balance
After 2022-12-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-12-06 · Exercise / conversion · Acquired 1,734 · Balance 1,734 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). Row 2 · 2022-12-06 · Sale · Disposed 440 · Balance 1,294 F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,466 |
Reported balance
After 2022-12-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-06 · Exercise / conversion · Disposed 1,734 · Balance 3,466 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). F3: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 28, 2026 16:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 7,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001441461-26-000005 · ownership.xml · derivative · entry 2 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These restricted stock units vested on August 27, 2026. F2 · derivative.expiration_date: These restricted stock units vested on August 27, 2026. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 16:15 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 7,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001441461-26-000005 · ownership.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 8, 2026 22:29 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 17,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071469 · tm2617186-1_4seq1.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,629 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:03 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 28,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-064716 · tm2519510-6_4seq1.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,887 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 30, 2026 or the day immediately prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 23:25 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 5,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-069785 · tm2416741-3_4seq1.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,740 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 10:11 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084974 · tm2321997-3_4seq1.xml · nonDerivative · entry 2 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F3 · shares: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 10:11 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084974 · tm2321997-3_4seq1.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F2 · shares: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,734 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060586 · doc4.xml · derivative · entry 3 Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 1,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). F3 · derivative.exercise_date: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. F3 · derivative.expiration_date: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 440 | $4.92 | $2,165.46 |
DisclosureSEC source: 0001209191-22-060586 · doc4.xml · nonDerivative · entry 2 Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294 F2 · kind: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations Read SEC document |
| December 06, 2022 Filed Dec 10, 2022 00:38 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060586 · doc4.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 21:15 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 260,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021793 · doc4.xml · derivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires not disclosed F1 · derivative.exercise_date: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: The performance stock units ("PSUs") vest on April 5, 2025 based the total shareholder return ("TSR") of the issuer over the period from April 1, 2022 to March 31, 2025 and are subject to the continuous service of the reporting person with the issuer. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs, depending on the TSR milestone achieved. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 23, 2022 Filed Mar 28, 2022 11:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 260,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021212 · doc4.xml · derivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. F1 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 21:20 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 400,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060610 · doc4.xml · derivative · entry 3 Glickman Mark A · CIK 0001441461 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F3 · shares: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer. F3 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer. F3 · balance_after: Each RSU represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on October 15, 2024, subject to the continued service of the reporting person with the issuer. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 21:20 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 260,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060610 · doc4.xml · derivative · entry 2 Glickman Mark A · CIK 0001441461 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires not disclosed F2 · shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. F2 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. F2 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. F2 · derivative.underlying_shares: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. F2 · balance_after: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. Read SEC document |
| October 15, 2021 Filed Oct 15, 2021 21:20 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantPerformance Stock Units · Derivative | 260,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060610 · doc4.xml · derivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires not disclosed F1 · shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.exercise_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.expiration_date: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · derivative.underlying_shares: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. F1 · balance_after: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. No PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:27 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy · Derivative | 26,625 | $0.00 Strike: $61.34 | $0.00 |
DisclosureSEC source: 0001179110-20-000171 · edgar.xml · derivative · entry 2 Glickman Mark A · CIK 0001441461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,625 Underlying: Common Stock · 26,625 shares Expires 2030-01-02 F1 · derivative.exercise_date: The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:27 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 5,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000171 · edgar.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,925 F1 · shares: The award will vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2020. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:15 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 5,725 | $1.70 | $9,732.50 |
DisclosureSEC source: 0001104659-18-019362 · a4.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,188 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 15,184 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantEmployee Stock Option (right to buy) · Derivative | 92,621 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032415 · a4.xml · derivative · entry 2 Glickman Mark A · CIK 0001441461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,621 Underlying: Common Shares, without par value · 92,621 shares Expires 2027-05-11 F3 · derivative.exercise_date: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date, subject to continued employment or service to the Company. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 80,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032415 · a4.xml · nonDerivative · entry 1 Glickman Mark A · CIK 0001441461 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,913 F1 · kind: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company. F2 · balance_after: Includes 58,380 shares of Common Stock and 197,533 Restricted Stock Units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.